Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04234997 · ClinicalTrials.gov registry record · Phase 2
Suvorexant to Reduce Symptoms of Nicotine Use
A Phase 2 study of Smoking Cessation, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04234997: Completed Phase 2 study of Smoking Cessation, sponsored by The University of Texas Health Science Center, Houston.
NCT04234997 is a Phase 2 study of Smoking Cessation that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 14 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04234997, a Phase 2 study of Smoking Cessation, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use disorder
Primary Outcome
The VAS total score ranges from 1(none) to 10(extreme stress);a higher score indicating a worse outcome.
Conditions Studied
Interventions
- DRUG Suvorexant 20 mg
- DRUG Suvorexant 0mg
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 2 |
What the finished NCT04234997 record still lists
NCT04234997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Suvorexant 20 mg is the first listed.
NCT04234997 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04234997 about?
NCT04234997 is a clinical study titled "Suvorexant to Reduce Symptoms of Nicotine Use". The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of suvorexant on sleep metrics in a sample of individuals with tobacco use diso...
What is the current status of trial NCT04234997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-08-23. Estimated completion is 2024-08-22.
What conditions does trial NCT04234997 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT04234997?
The interventions under investigation include: Suvorexant 20 mg (DRUG), Suvorexant 0mg (DRUG).
Who is sponsoring clinical trial NCT04234997?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04234997 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04234997's enrollment target sits among peer trials
14 183rd of 188 higher than 6 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy